Hisamitsu Pharmaceutical Co (FSE:4530) LT-Debt-to-Total-Asset: 0.00 (As of Nov. 2025)

What is Hisamitsu Pharmaceutical Co LT-Debt-to-Total-Asset?

Hisamitsu Pharmaceutical Co FSE:4530 89 LT-Debt-to-Total-Asset is 0.00 as of Nov. 2025. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hisamitsu Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Nov. 2025 was 0.00.

Hisamitsu Pharmaceutical Co's long-term debt to total assets ratio declined from Nov. 2024 (0.01) to Nov. 2025 (0.00). It may suggest that Hisamitsu Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Hisamitsu Pharmaceutical Co (FSE:4530) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hisamitsu Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Hisamitsu Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Feb25

Feb26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

0.00

Hisamitsu Pharmaceutical Co Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.00	0.00	0.00

89GF Score

Hisamitsu Pharmaceutical Co Inc FSE:4530

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Hisamitsu Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Hisamitsu Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (A: Feb. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Feb. 2026 )	/	Total Assets (A: Feb. 2026 )
	=	1124	/	367162
	=	0.00

Hisamitsu Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Nov. 2025 is calculated as

LT Debt to Total Assets (Q: Nov. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Nov. 2025 )	/	Total Assets (Q: Nov. 2025 )
	=	1431	/	342309
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Hisamitsu Pharmaceutical Co (FSE:4530) has a LT-Debt-to-Total-Asset of 0.00 as of Nov. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hisamitsu Pharmaceutical Co and its competitors.

Is Hisamitsu Pharmaceutical Co's LT-Debt-to-Total-Asset too high?

Hisamitsu Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.

How does Hisamitsu Pharmaceutical Co's LT-Debt-to-Total-Asset compare to ESPR and AMPH?

Hisamitsu Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Hisamitsu Pharmaceutical Co stock overvalued right now?

Hisamitsu Pharmaceutical Co (FSE:4530) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current LT-Debt-to-Total-Asset is 0.00 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

LT-Debt-to-Total-Asset: 0.00
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
GF Score™: 89/100

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ESPR AMPH ETON IRWD PCRX BIOA TLRY AQST EOLS COLL XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges HTSUY:USA

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017

Website https://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.

89GF Score

Get the complete analysis for FSE:4530

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00

Price

円3,237.07

GF Value

View FSE:4530 Analysis

See LT-Debt-to-Total-Asset data for all stocks →